Results 1 to 10 of about 5,664,310 (354)

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. [PDF]

New England Journal of Medicine, 2016
Background The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. Methods In this double-blind trial, we randomly assigned patients with type 2 diabetes
S. Marso, Gilbert H. Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R. Poulter, Lasse S Ravn, William M Steinberg, Mette Stockner, B. Zinman, R. Bergenstal, J. B. Buse   +14 more
semanticscholar   +3 more sources

Real-time continuous glucose monitoring versus self-monitoring of blood glucose in adults with insulin-treated type 2 diabetes: a protocol for a randomised controlled single-centre trial

BMJ Open, 2021
Introduction Medical treatment options for type 2 diabetes (T2D) have increased over the last decade and enhance the possibility of individualised treatment strategies where insulin is still one of them. In spite of the advancements in treatment options,
Kirsten Nørgaard, Nanna Lind, Dorte Lindqvist Hansen, Signe Sætre Rasmussen   +3 more
doaj   +1 more source

Differences in lipid and blood pressure measurements between individuals with type 1 diabetes and the general population: a cross-sectional study

BMJ Open, 2023
Objectives Cardiovascular disease (CVD) is a precarious complication of type 1 diabetes (T1D). Alongside glycaemic control, lipid and blood pressure (BP) management are essential for the prevention of CVD.
Bruce H R Wolffenbuttel, Melanie M van der Klauw, Henk-Jan Aanstoot, Rita Delphine Maiko Varkevisser, Dick Mul   +4 more
doaj   +1 more source

Residual C-peptide secretion and hypoglycemia awareness in people with type 1 diabetes

BMJ Open Diabetes Research & Care, 2021
Introduction This study aimed to assess the association between fasting serum C-peptide levels and the presence of impaired awareness of hypoglycemia (IAH) in people with type 1 diabetes.Research design and methods We performed a cross-sectional study ...
Giesje Nefs, Bruce H R Wolffenbuttel, Peter R van Dijk, Petronella H Geelhoed-Duijvestijn, Henk-Jan Aanstoot, Martine J Wellens, Charlotte E Vollenbrock, Pim Dekker, Lianne S M Boesten, Martine M C de Vries-Velraeds   +9 more
doaj   +1 more source

Identification of pathogenic GCK variants in patients with common type 2 diabetes can lead to discontinuation of pharmacological treatment

Molecular Genetics and Metabolism Reports, 2023
Background: Functionally disruptive variants in the glucokinase gene (GCK) cause a form of mild non-progressive hyperglycemia, which does not require pharmacological treatment.
Anne Cathrine Baun Thuesen, Rasmus Tanderup Jensen, Henrik Maagensen, Maja Refshauge Kristiansen, Henrik Toft Sørensen, Allan Vaag, Henning Beck-Nielsen, Oluf B. Pedersen, Niels Grarup, Jens Steen Nielsen, Jørgen Rungby, Anette Prior Gjesing, Heidi Storgaard, Tina Vilsbøll, Torben Hansen   +14 more
doaj   +1 more source

Type 2 Innate Lymphoid Cells: Protectors in Type 2 Diabetes

Frontiers in Immunology, 2021
Type 2 innate lymphoid cells (ILC2) are the innate counterparts of Th2 cells and are critically involved in the maintenance of homeostasis in a variety of tissues.
Jacob D. Painter, Omid Akbari
doaj   +1 more source

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Diabetes Care, 2022
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated ...
M. Davies, V. Aroda, B. Collins, R. Gabbay, Jennifer B. Green, N. Maruthur, Sylvia E. Rosas, S. Del Prato, C. Mathieu, G. Mingrone, P. Rossing, T. Tankova, A. Tsapas, J. Buse   +13 more
semanticscholar   +1 more source

Tirzepatide for type 2 diabetes

Drugs in Context, 2023
One in ten adults worldwide is living with diabetes, with 95% having type 2 diabetes (T2D). Sustained glycaemic control in people with T2D is difficult to achieve despite recent advances in T2D management with the advent of glucagon-like peptide 1 ...
Sarah L Anderson, Joel C Marrs
doaj   +1 more source

Ethnic differences in adiposity and diabetes risk – insights from genetic studies [PDF]

, 2020
Type 2 diabetes is more common in non-Europeans and starts at a younger age and at lower BMI cut-offs. This review discusses the insights from genetic studies about pathophysiological mechanisms which determine risk of disease with a focus on the role of
Bell, J.D., Bell, J.D., Thomas, E.L., Thomas, E.L., Whitcher, B., Whitcher, B., Yaghootkar, H., Yaghootkar, H.   +7 more
core   +2 more sources

Assessment of the operative memory capacity based on endogenous evoked potentials (P300 method) without neuropsychological testing

Анналы клинической и экспериментальной неврологии, 2017
We analyzed the dependence of the operative memory (OP) capacityon P300 parameters in healthy individuals and patientswith a varying degree of memory impairments.
V. V. Gnezditskiy, A. V. Chatskaya, O. S. Korepina, O. I. Klochkova   +3 more
doaj   +1 more source